Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings, Inc.

CRBP

Insider Sentiment (TTM):

Last Purchase:2026-06-03Last Sale:2026-06-10Shares Purchased (TTM):9,000Shares Sold (TTM):93,497

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:12,687,304Shares Outstanding:18,706,622Institutional Ownership Pct.:67.82%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	23	26	28	27	20	19	17	19	24	14	14	11
Short Term Investments	95	113	135	77	97	114	132	140	123	106	7	17
Restricted Cash Current	0	0	1	0	0	0	0	0	0	0	0	0
Prepaid Expense And Other Assets Current	5	5	3	3	6	4	4	1	1	1	2	2
Assets Current	123	144	167	108	123	137	153	161	148	122	24	31
Restricted Cash Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	0	0	0	0	0	0	0	1	1	1	1	1
Operating Lease Right Of Use Asset	4	1	1	1	2	2	2	2	3	3	3	3
Other Assets Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Assets	127	144	168	110	125	140	156	164	152	126	28	36
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	0	2	3	4	4	5	3	1	2	3	5
Notes Payable Current	-	-	-	-	-	-	0	0	0	0	0	0
Accrued Liabilities Current	15	16	17	13	8	6	5	7	10	9	11	8
Operating Lease Liability Current	1	1	2	2	2	2	2	2	2	1	1	1
Liabilities Current	21	18	21	17	13	12	12	12	24	26	32	32
Derivative Liabilities Current	-	-	-	-	-	-	0	0	0	0	0	0
Operating Lease Liability Noncurrent	-	-	0	0	1	1	2	2	2	3	3	4
Liabilities	25	18	21	17	14	13	13	14	26	29	35	36
Stockholders Equity
Other Long Term Debt Current	-	-	-	-	-	-	-	-	-	13	16	18
Loans Payable	-	-	-	-	-	-	0	0	11	-	16	-
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Long Term Debt Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Entertainment License Agreement For Program Materi…	-	-	-	-	-	-	-	-	-	-	-	1
Additional Paid In Capital	716	705	703	627	623	621	619	618	580	541	430	429
Retained Earnings Accumulated Deficit	-613	-578	-555	-535	-512	-494	-477	-467	-454	-444	-437	-429
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	-0	0	0	-0	-0	-0	-0
Stockholders Equity	102	126	148	92	111	127	142	150	126	97	-7	0
Liabilities And Stockholders Equity	127	144	168	110	125	140	156	164	152	126	28	36
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	19	18	18	13	12	12	12	12	11	11	4	4
Shares Outstanding	19	18	18	13	12	12	12	12	11	11	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-33.86%	-19.07%	-21.52%	-	-	-	-	-	-	-	-	-
2025	18.72%	18.40%	48.16%	5.28%	36.07%	89.66%	-8.49%	-29.67%	-26.09%	6.49%	7.85%	-17.17%
2024	7.62%	13.78%	45.99%	15.56%	-60.48%	-69.19%	-3.78%	-31.16%	-43.20%	-27.03%	13.23%	7.85%
2023	-	-	-	3.26%	4.66%	-19.10%	54.76%	43.81%	602.14%	-10.34%	-13.03%	-3.99%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.71	7.92	8.07	6.31	9.21	11.82	12.94	13.84	6.18	4.69	0.74	0.99
Quick Ratio	5.49	7.64	7.92	6.11	8.77	11.45	12.64	13.73	6.14	4.64	0.66	0.92
Working Capital	101.27M	125.43M	146.26M	90.51M	109.49M	125.74M	141.16M	149.27M	124.33M	95.77M	-8.35M	-336.36K
Leverage & Debt
Debt to Equity	0.24	0.14	0.14	0.19	0.13	0.10	0.09	0.09	0.21	0.30	-5.09	115.30
Interest Coverage TTM	-	-	-	-	-175.95	-56.99	-26.03	-9.73	-7.52	-6.56	-8.13	-13.84
Debt Ratio	0.19	0.13	0.12	0.16	0.11	0.09	0.09	0.08	0.17	0.23	1.24	0.99
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-5.25	-4.52	-5.90	-5.49	-4.73	-4.12	-3.68	-3.22	-3.16	-4.06	-10.31	-10.73
Free Cash Flow Per Share TTM	-4.47	-3.94	-4.84	-4.84	-4.73	-4.12	-3.83	-3.07	-2.72	-3.48	-8.34	-8.49
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	75.84%	68.09%	95.32%	74.44%	65.72%	48.97%	-9.85%	-18.46%	-24.29%	-33.36%	5.33%	13.74%
EPS Growth (1Y)	10.90%	9.64%	60.10%	70.30%	49.64%	1.46%	-64.26%	-69.98%	-70.70%	-66.47%	1.51%	7.24%
Valuation Metrics
P/E TTM	-1.79	-2.08	-1.38	-2.31	-1.46	-1.29	-3.20	-6.40	-14.30	-9.66	-0.59	-0.63
P/B TTM	1.78	1.39	0.73	1.69	0.76	0.51	0.90	1.65	3.98	3.36	-3.79	95.56
Market Cap	182.04M	175.66M	108.40M	155.69M	84.46M	64.79M	128.80M	247.86M	500.16M	326.10M	26.14M	29.82M
Enterprise Value	158.67M	149.99M	79.91M	128.70M	64.42M	45.89M	111.60M	228.44M	476.55M	312.19M	12.72M	18.57M
Calculated Values
Free Cash Flow TTM	-86.68M	-73.65M	-64.49M	-59.51M	-57.90M	-50.25M	-41.79M	-36.86M	-30.09M	-28.95M	-36.10M	-37.55M
Net Debt	-23.37M	-25.66M	-28.49M	-26.98M	-20.04M	-18.90M	-17.20M	-19.42M	-23.61M	-13.91M	-13.42M	-11.25M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-10Sale

Owner: Altmeyer, Anne

Title: -

Shares: 2,412

Price/Share: $7.91

Value: $19,078.92

Shares Owned: 7,579

Relationship: Director

Ownership: Direct

2026-06-10Sale

Owner: Jenkins, John Kenneth

Title: -

Shares: 4,800

Price/Share: $7.91

Value: $37,968.00

Shares Owned: 3,833

Relationship: Director

Ownership: Direct

2026-06-10Sale

Owner: Kung, Winston

Title: -

Shares: 2,026

Price/Share: $7.91

Value: $16,025.66

Shares Owned: 12,140

Relationship: Director

Ownership: Direct

2026-06-03Purchase

Owner: Saxena, Nishant C

Title: Chief Business Officer

Shares: 9,000

Price/Share: $7.58

Value: $68,220.00

Shares Owned: 75,300

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Smethurst, Dominic

Title: Chief Medical Officer

Shares: 6,097

Price/Share: $8.30

Value: $50,605.10

Shares Owned: 89,790

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-10	Altmeyer, Anne	Director	-	Direct	Sale	2,412	7.91	$19,078.92	7,579	4
2026-06-10	Jenkins, John Kenneth	Director	-	Direct	Sale	4,800	7.91	$37,968.00	3,833	4
2026-06-10	Kung, Winston	Director	-	Direct	Sale	2,026	7.91	$16,025.66	12,140	4
2026-06-03	Saxena, Nishant C	Officer	Chief Business Officer	Direct	Purchase	9,000	7.58	$68,220.00	75,300	4
2026-03-02	Smethurst, Dominic	Officer	Chief Medical Officer	Direct	Sale	6,097	8.30	$50,605.10	89,790	4
2026-02-17	Hodgson, Ian	Officer	Chief Operating Officer	Direct	Sale	847	7.38	$6,250.86	51,080	4
2026-02-13	Moran, Sean F.	Officer	Chief Financial Officer	Direct	Sale	4,701	7.78	$36,573.78	96,694	4
2026-02-13	Cohen, Yuval	Director,Officer	Chief Executive Officer	Direct	Sale	13,871	7.78	$107,916.38	174,316	4
2026-02-03	Smethurst, Dominic	Officer	Chief Medical Officer	Direct	Sale	3,285	8.09	$26,575.65	95,887	4
2026-02-03	Hodgson, Ian	Officer	Chief Operating Officer	Direct	Sale	2,415	8.09	$19,537.35	51,927	4
2025-12-11	Chen, Bihua, Cormorant Gl…	TenPercentOwner	-	Indirect	Sale	30,029	11.46	$344,132.34	2,344,971	4
2025-10-27	Cohen, Yuval	Director,Officer	Chief Executive Officer	Direct	Sale	8,973	17.14	$153,797.22	138,187	4
2025-10-24	Moran, Sean F.	Officer	Chief Financial Officer	Direct	Sale	12,981	17.02	$220,936.62	73,313	4
2025-10-20	Altmeyer, Anne	Director	-	Direct	Sale	1,060	20.50	$21,730.00	6,191	4
2025-05-30	Altmeyer, Anne	Director	-	Direct	Sale	1,392	7.25	$10,092.00	1,391	4
2025-05-30	Jenkins, John Kenneth	Director	-	Direct	Sale	2,783	7.35	$20,455.05	33	4
2025-03-06	Smethurst, Dominic	Officer	Chief Medical Officer	Direct	Sale	6,393	6.78	$43,344.54	70,807	4
2025-02-14	Cohen, Yuval	Director,Officer	Chief Executive Officer	Direct	Sale	7,134	8.76	$62,493.84	138,187	4
2025-02-14	Moran, Sean F.	Officer	Chief Financial Officer	Direct	Sale	2,792	8.76	$24,457.92	73,313	4
2024-09-20	Cormorant, Global Healthc…	TenPercentOwner	-	Indirect	Purchase	350,000	19.93	$6,975,500.00	2,375,000	4
2024-06-18	Cohen, Yuval	Director,Officer	Chief Executive Officer	Direct	Sale	22,938	42.24	$968,901.12	77,221	4
2024-06-18	Moran, Sean F.	Officer	Chief Financial Officer	Direct	Sale	1,958	42.12	$82,470.96	48,605	4
2024-03-08	Chen, Bihua, Cormorant Gl…	TenPercentOwner	-	Indirect	Purchase	300,000	43.76	$13,128,000.00	2,025,000	4
2024-02-02	Cormorant, Asset Manageme…	TenPercentOwner	-	Indirect	Purchase	750,000	19.00	$14,250,000.00	1,475,000	4
2024-01-26	Chen, Bihua, Cormorant Gl…	TenPercentOwner	-	Indirect	Purchase	282,632	32.17	$9,092,271.44	725,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

67.82%

Inst. Shares: 12,687,304

Shares Outstanding: 18,706,622

2025-12-31

98.73%

Inst. Shares: 13,148,552

Shares Outstanding: 13,317,116

2025-09-30

70.56%

Inst. Shares: 8,684,235

Shares Outstanding: 12,307,298

2025-06-30

72.64%

Inst. Shares: 8,892,062

Shares Outstanding: 12,240,443

2025-03-31

74.42%

Inst. Shares: 9,080,870

Shares Outstanding: 12,202,092

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	12,687,304	18,706,622	67.82%
2025-12-31	13,148,552	13,317,116	98.73%
2025-09-30	8,684,235	12,307,298	70.56%
2025-06-30	8,892,062	12,240,443	72.64%
2025-03-31	9,080,870	12,202,092	74.42%
2024-12-31	10,712,940	10,915,413	98.15%
2024-09-30	11,351,977	12,014,700	94.48%
2024-06-30	10,211,406	11,053,241	92.38%
2024-03-31	8,116,485	8,310,508	97.67%
2023-12-31	752,306	4,327,568	17.38%
2023-09-30	741,862	4,423,617	16.77%
2023-06-30	738,334	4,277,701	17.26%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Corbus Pharmaceuticals Holdings, Inc. (CRBP) — SEC Financial Statements & Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a pharmaceutical preparations company, incorporated in DE. Corbus Pharmaceuticals Holdings, Inc. trades on Nasdaq as: CRBP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Corbus Pharmaceuticals Holdings, Inc. reported a Debt-to-Equity ratio of 0.24x, a Price-to-Book (P/B) ratio of 1.78x (TTM), at a market cap of $182.04M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.24x
P/B TTM: 1.78x
Market Cap: $182.04M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Corbus Pharmaceuticals Holdings, Inc. in?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) operates in the Pharmaceutical Preparations industry.

What is CRBP's market cap?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a market capitalization of $182.04M as of 2026-06-30.

What exchange does CRBP trade on?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades on the Nasdaq.

Where is Corbus Pharmaceuticals Holdings, Inc. incorporated?

Corbus Pharmaceuticals Holdings, Inc. is incorporated in DE.